No Data
Jiangsu Jindick Biotechnology Co., Ltd. 2024 Annual Results Forecast
Jiangsu Jindick Biotechnology Co., Ltd. Report for the Third Quarter of 2024
Jindike (688670.SH) released its performance for the first three quarters, with a net loss of 53.4614 million yuan.
Jindike (688670.SH) released the third quarter report of 2024, with revenue in the first three quarters of the company reaching 388...
Jindike (688670.SH): The net loss for the first three quarters was 53.46 million yuan.
On October 24th, Golden Dick (688670.SH) released its third quarter report, with revenue of 38.899 million yuan, a year-on-year decrease of 67.81%, net loss of 53.46 million yuan, non-recurring net loss of 61.53 million yuan, and basic earnings per share of -0.43 yuan.
Kindik (688670.SH): There are currently no related products or research projects for monkeypox vaccines.
On September 20, Gedlonhui reported that Jindike (688670.SH) stated on the investor interaction platform that the company currently has no monkeypox vaccine-related products or research and development projects. Investors are reminded to invest cautiously and pay attention to investment risks.
Jiangsu Kindk Biosciences Co., Ltd.'s 2024 interim report in full.
More Unpleasant Surprises Could Be In Store For Jiangsu Gdk Biological Technology Co., Ltd's (SHSE:688670) Shares After Tumbling 27%
